Kempharm Z Score

KMPH -  USA Stock  

USD 10.99  0.23  2.14%

Altman Z Score is one of the simplest fundamental models to determine how likely your company is to fail. The module uses available fundamental data of a given equity to approximate the Altman Z score. Altman Z Score is determined by evaluating five fundamental price points available from the company's current public disclosure documents. Please see Kempharm Piotroski F Score and Kempharm Valuation analysis.

Search Z Score 

 
Refresh
Kempharm Market Capitalization is most likely to decrease significantly in the upcoming years. The last year's value of Market Capitalization was reported at 50.78 Million. The current Working Capital is estimated to increase to about 868.3 K, while Capital Expenditure is projected to decrease to (35.6 K). Kempharm Selling General and Administrative Expense is most likely to increase significantly in the upcoming years. The last year's value of Selling General and Administrative Expense was reported at 7.92 Million. The current Weighted Average Shares is estimated to increase to about 4.3 M, while Consolidated Income is projected to decrease to (13.8 M).

Kempharm Z Score Analysis

Kempharm's Z-Score is a simple linear, multi-factor model that measures the financial health and economic stability of a company. The score is used to predict the probability of a firm going into bankruptcy within next 24 months or two fiscal years from the day stated on the accounting statements used to calculate it. The model uses five fundamental business ratios that are weighted according to algorithm of Professor Edward Altman who developed it in the late 1960s at New York University..
 2020 2021 (projected)
Interest Expense4.79 M4.75 M
Gross Profit13.29 M14.56 M
Z Score 
 = 
Sum Of  
 
5 Factors 
More About Z Score | All Equity Analysis

Current Kempharm Z Score

    
  61.0  
Most of Kempharm's fundamental indicators, such as Z Score, are part of a valuation analysis module that helps investors searching for stocks that are currently trading at higher or lower prices than their real value. If the real value is higher than the market price, Kempharm is considered to be undervalued, and we provide a buy recommendation. Otherwise, we render a sell signal.
First Factor
 = 
1.2 * (
Working Capital
/
Total Assets )
Second Factor
 = 
1.4 * (
Retained Earnings
/
Total Assets )
Thrid Factor
 = 
3.3 * (
EBITAD
/
Total Assets )
Fouth Factor
 = 
0.6 * (
Market Value of Equity
/
Total Liabilities )
Fifth Factor
 = 
0.99 * (
Revenue
/
Total Assets )

Kempharm Z Score Driver Correlations

Understanding the fundamental principles of building solid financial models for Kempharm is extremely important. It helps to project a fair market value of Ford stock properly, considering its historical fundamentals such as Z Score. Since Kempharm's main accounts across its financial reports are all linked and dependent on each other, it is essential to analyze all possible correlations between related accounts. However, instead of reviewing all of Kempharm's historical financial statements, investors can examine the correlated drivers to determine its overall health. This can be effectively done using a conventional correlation matrix of Kempharm's interrelated accounts and indicators.
To calculate Z-Score one would need to know current working capital of the company, its total assets, and liabilities, amount of latest retained earnings as well as earnings before interest and tax. Z-Score can be used to compare the odds of bankruptcy of companies in a similar line of business or firms operating in the same industry. Companies with Z-Scores above 3.1 are generally considered to be stable and healthy with a low probability of bankruptcy. Scores that fall between 1.8 and 3.1 lie in a so-called 'grey area' with scores of less than 1, indicating the high probability of distress. Z Score is used widely by financial auditors, accountants, money managers, loan processers, wealth advisers, as well as day traders. In the last 25 years, many financial models that utilize z score has been proved to be successful as a predictor of corporate bankruptcy.
Compare to competition

Based on the company's disclosures, Kempharm has a Z Score of 61. This is much higher than that of the Healthcare sector and notably higher than that of the Biotechnology industry. The z score for all United States stocks is notably lower than that of the firm.

Kempharm Z Score Peer Comparison

Stock peer comparison is one of the most widely used and accepted methods of equity analyses. It analyses Kempharm's direct or indirect competition against its Z Score to detect undervalued stocks with similar characteristics or determine the stocks which would be a good addition to a portfolio. Peer analysis of Kempharm could also be used in its relative valuation, which is a method of valuing Kempharm by comparing valuation metrics of similar companies.
Kempharm is currently under evaluation in z score category among related companies.

Kempharm Current Valuation Drivers

We derive many important indicators used in calculating different scores of Kempharm from analyzing Kempharm's financial statements. These drivers represent accounts that assess Kempharm's ability to generate profits relative to its revenue, operating costs, and shareholders' equity. Below are some of Kempharm's important valuation drivers and their relationship over time.
201620172018201920202021 (projected)
Average Assets99 M64.11 M30.53 M14.07 M10.91 M11.19 M
Earnings Before Interest Taxes and Depreciation Amortization EBITDA(10.85 M)(37.32 M)(50.8 M)(19.38 M)(7.74 M)(8.35 M)
Earnings Before Interest Taxes and Depreciation Amortization USD(10.85 M)(37.32 M)(50.8 M)(19.38 M)(7.74 M)(8.35 M)
Earnings before Tax(16.53 M)(43.43 M)(56.59 M)(24.54 M)(12.79 M)(13.8 M)
Average Equity(9.91 M)(44.71 M)(81.28 M)(75.36 M)(65.07 M)(70.21 M)
Enterprise Value112.15 M142.95 M135.37 M85.21 M114.02 M118.94 M
Free Cash Flow(30.41 M)(33.28 M)(54.22 M)(23.76 M)(1.97 M)(2.13 M)
Invested Capital152.37 M122.46 M77.67 M81.05 M69.7 M76.98 M
Invested Capital Average147.93 M137.1 M92.2 M76.47 M19.55 M20.07 M
Market Capitalization43.21 M59.36 M47.09 M12.6 M50.78 M61.81 M
Tangible Asset Value84.89 M52.46 M26.75 M10.51 M11.21 M11.5 M
Working Capital67.72 M34.39 M11.72 M1.54 M846 K868.26 K

Kempharm Fundamentals

About Kempharm Fundamental Analysis

The Macroaxis Fundamental Analysis modules help investors analyze Kempharm's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Kempharm using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Kempharm based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Please read more on our fundamental analysis page.
KemPharm, Inc., a specialty pharmaceutical company, discovers and develops various proprietary prodrugs to treat serious medical conditions in the United States. The company was incorporated in 2006 and is headquartered in Celebration, Florida. Kempharm operates under Biotechnology classification in the United States and is traded on NASDAQ Exchange. It employs 22 people.

Kempharm Investors Sentiment

The influence of Kempharm's investor sentiment on the probability of its price appreciation or decline could be a good factor in your decision-making process regarding taking a position in Kempharm. The overall investor sentiment generally increases the direction of a stock movement in a one-year investment horizon. However, the impact of investor sentiment on the entire stock markets does not have a solid backing from leading economists and market statisticians.

Current Sentiment - KMPH

Kempharm Investor Sentiment

Most of Macroaxis users are now bullish on Kempharm. What is your trading attitude regarding investing in Kempharm? Are you bullish or bearish?
Bullish
Bearish
98% Bullish
2% Bearish
Skip

Becoming a Better Investor with Macroaxis

Macroaxis puts the power of mathematics on your side. We analyze your portfolios and positions such as Kempharm using complex mathematical models and algorithms, but make them easy to understand. There is no real person involved in your portfolio analysis. We perform a number of calculations to compute absolute and relative portfolio volatility, correlation between your assets, value at risk, expected return as well as over 100 different fundamental and technical indicators.

Build Optimal Portfolios

Align your risk with return expectations

Fix your portfolio
By capturing your risk tolerance and investment horizon Macroaxis technology of instant portfolio optimization will compute exactly how much risk is acceptable for your desired return expectations
Please see Kempharm Piotroski F Score and Kempharm Valuation analysis. Note that the Kempharm information on this page should be used as a complementary analysis to other Kempharm's statistical models used to find the right mix of equity instruments to add to your existing portfolios or create a brand new portfolio. You can also try Competition Analyzer module to analyze and compare many basic indicators for a group of related or unrelated entities.

Complementary Tools for Kempharm Stock analysis

When running Kempharm price analysis, check to measure Kempharm's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Kempharm is operating at the current time. Most of Kempharm's value examination focuses on studying past and present price action to predict the probability of Kempharm's future price movements. You can analyze the entity against its peers and financial market as a whole to determine factors that move Kempharm's price. Additionally, you may evaluate how the addition of Kempharm to your portfolios can decrease your overall portfolio volatility.
Portfolio Anywhere
Track or share privately all of your investments from the convenience of any device
Go
Performance Analysis
Check effects of mean-variance optimization against your current asset allocation
Go
Fundamentals Comparison
Compare fundamentals across multiple equities to find investing opportunities
Go
Price Transformation
Use Price Transformation models to analyze depth of different equity instruments across global markets
Go
Crypto Correlations
Use cryptocurrency correlation module to diversify your cryptocurrency portfolio across multiple coins
Go
Portfolio Holdings
Check your current holdings and cash postion to detemine if your portfolio needs rebalancing
Go
The market value of Kempharm is measured differently than its book value, which is the value of Kempharm that is recorded on the company's balance sheet. Investors also form their own opinion of Kempharm's value that differs from its market value or its book value, called intrinsic value, which is Kempharm's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Kempharm's market value can be influenced by many factors that don't directly affect Kempharm underlying business (such as pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Kempharm's value and its price as these two are different measures arrived at by different means. Investors typically determine Kempharm value by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Kempharm's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.